SCHEMBL4120370

SCHEMBL4120370

CNC(=O)c1cnn2c(-c3ccc(C(F)(F)F)cc3)c(-c3ccccc3Cl)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.41
GPR119 Q8TDV5 5/20 0.41
MAPT P10636 1/20 0.38
RECQL P46063 1/20 0.38
RPS6KA3 P51812 1/20 0.38
SCN9A Q15858 2/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TGFBR1 P36897 1/20 0.37
NR3C1 P04150 2/20 0.37
PDK2 Q15119 1/20 0.37
LMNA P02545 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
HCRTR1 O43613 1/20 0.37
LCK P06239 1/20 0.37
HCK P08631 1/20 0.37
SRC P12931 1/20 0.37
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4115056 0.90 GPR119 (0.41) KDRGPR119MAPTRECQLRPS6KA3
SCHEMBL2055567 0.90 GPR119 (0.39) GPR119RPS6KA3SCN9AKDM4ENR3C1
SCHEMBL2055528 0.89 GPR119 (0.42) KDRGPR119MAPTKDM4EALDH1A1
SCHEMBL4115655 0.89 GPR119 (0.43) GPR119MAPTRPS6KA3KDM4EALDH1A1
SCHEMBL4127223 0.89 GPR119 (0.37) GPR119MAPTSCN9AALDH1A1LMNA
SCHEMBL2084102 0.88 GPR119 (0.41) GPR119MAPTRPS6KA3SCN9AKDM4E
SCHEMBL2085843 0.86 DGAT1 (0.40) GPR119SCN9A
SCHEMBL2085842 0.86 DGAT1 (0.40) GPR119SCN9A
SCHEMBL2085340 0.86 GPR119 (0.39) GPR119NR3C1LMNATRPV1
SCHEMBL4115834 0.86 HCRTR1 (0.45) MAPTKDM4EALDH1A1TRPV1HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD KDR 1945/4885GPR119 2137/4885MAPT 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.